News

Each year, Clarivate / Web of Science publishes a list of the most cited researchers worldwide, categorized into 21 fields. Once again, Gustave Roussy and its Foundation rank among the most represented French institutions, reflecting its research's excellence and global influence.

The Institute is launching the Gustave Roussy Prize to mark the 150th anniversary of the birth of its visionary founder. With an endowment of €200,000, this scientific award will annually recognize a researcher whose discoveries in the fight against cancer have a major impact on patient care.

Professor Fabrice Barlesi is one of the key figures in the “MAKE IT ICONIC. Choose France” campaign, which promotes French audacity and innovation on a global scale.

For the fifth consecutive year, Newsweek magazine has ranked Gustave Roussy among the top five hospitals for oncology worldwide, highlighting its outstanding performance in both patient care and research.

Bringing together more than 31,000 international experts, the European Society of Medical Oncology (ESMO) annual congress is one of the highlights of global oncology. This year, it will be held from 13 to 17 September in Barcelona. Gustave Roussy, the leading cancer research and treatment centre in France and Europe, ranked fourth globally, is one...

From 31 May to 4 June, ASCO, the world’s largest cancer conference, is held in Chicago, USA. This year, Gustave Roussy’s physician-researchers participated in more than 130 abstracts selected by the conference’s scientific committee, testifying to the quality of the research conducted at the Institute, and its impact on a global scale.

The third edition of the Transatlantic Exchanges will be held in Boston on April 12th, 2024. Broadcast online live, this day of exchanges is an opportunity to follow high-level debates on the perspectives opened by liquid biopsy in precision oncology.

Le congrès ESMO Targeted Anticancer Therapies (TAT), organisé annuellement en Europe depuis 2018, est un événement incontournable dans le champ des nouvelles cibles et des nouveaux agents anticancéreux prometteurs, notamment ceux en essais précoces de développement clinique.

The ARC Foundation, which has joined forces with four European cancer charities under the ATTRACT grant, awards funding to the FOSTER-CabOS project. The grant obtained through this call for projects will fund a European Phase III clinical trial to evaluate cabozantinib, a tyrosine kinase inhibitor, to treat osteosarcoma, a rare type cancer.

The annual congress of the European Society of Medical Oncology (ESMO) will be held in Madrid from October 20 to 24, 2023. This key event in the world of oncology presents the main advances in clinical research. Gustave Roussy is one of the major players.